352 related articles for article (PubMed ID: 29032713)
1. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
Pollock RF; Muduma G
Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
[TBL] [Abstract][Full Text] [Related]
2. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
3. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
Pollock RF; Muduma G
J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
[No Abstract] [Full Text] [Related]
4. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.
Pollock RF; Muduma G
Clinicoecon Outcomes Res; 2017; 9():475-483. PubMed ID: 28848355
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anemia in England.
Iqbal TH; Kennedy N; Dhar A; Ahmed W; Pollock RF
J Med Econ; 2024; 27(1):392-403. PubMed ID: 38391240
[TBL] [Abstract][Full Text] [Related]
6. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
Pollock RF; Muduma G
Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
[TBL] [Abstract][Full Text] [Related]
7. Financial impact of intravenous iron treatments on the management of anaemia inpatients: a 1 year observational study.
Delpeuch A; Ruivard M; Abergel A; Aumaitre O; Boisgard S; Bagel S; Sautou V
Int J Clin Pharm; 2018 Jun; 40(3):686-692. PubMed ID: 29520555
[TBL] [Abstract][Full Text] [Related]
8. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Onken JE; Bregman DB; Harrington RA; Morris D; Buerkert J; Hamerski D; Iftikhar H; Mangoo-Karim R; Martin ER; Martinez CO; Newman GE; Qunibi WY; Ross DL; Singh B; Smith MT; Butcher A; Koch TA; Goodnough LT
Nephrol Dial Transplant; 2014 Apr; 29(4):833-42. PubMed ID: 23963731
[TBL] [Abstract][Full Text] [Related]
9. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
10. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
[TBL] [Abstract][Full Text] [Related]
11. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
Fell LH; Seiler-Mußler S; Sellier AB; Rotter B; Winter P; Sester M; Fliser D; Heine GH; Zawada AM
Nephrol Dial Transplant; 2016 Nov; 31(11):1835-1845. PubMed ID: 27190361
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
14. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
Wilson PD; Hutchings A; Jeans A; Macdougall IC
J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
[TBL] [Abstract][Full Text] [Related]
15. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C;
Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
[TBL] [Abstract][Full Text] [Related]
16. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
[TBL] [Abstract][Full Text] [Related]
17. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.
Reinisch W; Altorjay I; Zsigmond F; Primas C; Vogelsang H; Novacek G; Reinisch S; Thomsen LL
Scand J Gastroenterol; 2015; 50(10):1226-33. PubMed ID: 25900645
[TBL] [Abstract][Full Text] [Related]
18. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
[TBL] [Abstract][Full Text] [Related]
19. Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland.
Loughnane F; Muduma G; Pollock RF
Adv Ther; 2020 Mar; 37(3):1218-1232. PubMed ID: 32030608
[TBL] [Abstract][Full Text] [Related]
20. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
Bager P; Dahlerup JF
J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]